Lifestyle Features

Pennsylvania teen's birthday wish for more friends comes true

Wakisha Bailey  |  Posted Oct. 28 - 1:45 p.m.  |  Save Story

Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trial

Sriparna Roy, Reuters  |  Updated Oct. 28 - 10:07 a.m.  |  Save Story

Eli Lilly said on Wednesday its experimental next-generation obesity drug, retatrutide, outperformed Novo ​Nordisk's Ozempic on blood sugar control and delivered more than double the weight loss in a diabetes study.

Supplements brand Rho Nutrition explores sale, sources say

Abigail Summerville, Reuters  |  Updated Oct. 28 - 9:56 a.m.  |  Save Story

Rho Nutrition, a maker of ​liquid supplements and vitamins, is exploring a sale that could value the company at over $500 million, ‌according to people familiar with the matter.

Geron discontinues late-stage trial of blood cancer drug, shares plunge

Christy Santhosh, Reuters  |  Updated Oct. 28 - 9:08 a.m.  |  Save Story

Geron said on Wednesday it would halt a late-stage ​trial of its blood cancer treatment, marking a setback for the company's only commercial product, sending its shares plunging ‌20% in early trading.

GSK pipeline doubts, vaccine underperformance overshadow sales beat

Pushkala Aripaka, Reuters  |  Updated Oct. 28 - 9:05 a.m.  |  Save Story

GSK investors punished the British drugmaker on Wednesday despite a third-quarter sales and profit beat, focusing instead on questions over its ​drug pipeline and weak sales of vaccines, including its shingles shot Shingrix.

Biogen tops quarterly estimates on rare-disease drug strength

Christy Santhosh, Reuters  |  Updated Oct. 28 - 8:29 a.m.  |  Save Story

Biogen beat Wall Street estimates for third-quarter results on Wednesday, as robust ​demand for its rare-disease and Alzheimer's treatments helped offset declines in its under-pressure multiple sclerosis franchise.

A US cruise ship suspends a global voyage in Asia due to fuel costs, stranding 200 passengers

Sopheng Cheang, Associated Press  |  Updated Oct. 28 - 8:23 a.m.  |  Save Story

A U.S. cruise ship on a global voyage that touted its cabins as floating homes suspended its three-year voyage in Cambodia due to fuel costs, forcing hundreds of passengers to disembark.

Cooper Companies CEO White steps down

Siddhi Mahatole, Reuters  |  Updated Oct. 27 - 4:32 p.m.  |  Save Story

Cooper Companies said on Tuesday CEO Al White had ​stepped down, effective immediately, and board member Walt Rosebrough was elected executive chair as the medical device maker begins ‌its search for a new CEO.

Artiva to discontinue cell therapy after two patient deaths, cut workforce by 94%

Reuters  |  Updated Oct. 27 - 3:02 p.m.  |  Save Story

Artiva Biotherapeutics said on Tuesday it would halt the development ​of an experimental cell therapy for certain autoimmune conditions — its lead candidate — after two patient deaths, ‌sending its shares slumping 32%.

Eli Lilly international business chief Jonsson to retire; Yuffa to head global markets unit

Reuters  |  Updated Oct. 27 - 2:47 p.m.  |  Save Story

Eli Lilly said on Tuesday that Patrik Jonsson, executive vice ​president and president of its international business, will retire at the end of 2026 after a 36-year career ‌at the US drugmaker.

Food and household brands warn of more price hikes as Iran war costs bite

Alexander Marrow and Anuja Bharat Mistry, Reuters  |  Updated Oct. 27 - 2:43 p.m.  |  Save Story

The world's top consumer goods and food companies, from Coca-Cola and Procter & Gamble to Nestle and Reckitt, have warned of further ​price hikes next year to cover rising costs.

Centene lifts 2026 profit forecast, sees earnings growth continuing in 2027

Sneha S K and Padmanabhan Ananthan, Reuters  |  Updated Oct. 27 - 11:14 a.m.  |  Save Story

Centene raised its annual profit forecast and said it expects ​2027 earnings to be higher than this year, sending the health insurer's shares up 3%.

GSK to nearly double cancer medicines in clinical trials next year

Reuters  |  Updated Oct. 27 - 9:25 a.m.  |  Save Story

GSK said on Tuesday that it expects to almost double the ​number of cancer medicines it has in clinical trials next year, including those in early-stage studies, as it ‌tries to rebuild its oncology business.

Novartis books $2.2 billion hit from drug trial setbacks, but lifts guidance

Patricia Weiss, Bhanvi Satija and Marleen Kaesebier, Reuters  |  Updated Oct. 27 - 4:52 a.m.  |  Save Story

Novartis recorded about $2.2 billion in charges related to two drugs ​that failed in late-stage studies last month, even as it boosted its full-year profit expectations on Tuesday.

Indian drugmaker Cipla misses profit view on US weakness, shares slip

Kashish Tandon, Reuters  |  Updated Oct. 27 - 3:00 a.m.  |  Save Story

Indian drugmaker Cipla missed second-quarter profit estimates on Tuesday ​as a sharp slowdown in its US business eclipsed strong growth at home.

Reckitt lowers annual guidance on manufacturing struggles in North America

Alexander Marrow, Reuters  |  Updated Oct. 27 - 2:19 a.m.  |  Save Story

Dettol maker Reckitt lowered its annual revenue forecast on Tuesday and ​reported revenue growth below analyst expectations in the third quarter, hampered by a challenging consumer environment and manufacturing constraints in its North ‌American market.

Utah County nonprofit to close Heber City food pantry; announces layoffs

Sarah Earnshaw, KSL  |  Posted Oct. 26 - 6:48 p.m.  |  Save Story

Less than a week after announcing it needed $100,000 to remain operational through the end of the month, a Utah County nonprofit said it will close a food pantry location in Heber City.

Get a taste of Greece at historic Pocatello church's Fall Fest

Rett Nelson, EastIdahoNews  |  Posted Oct. 26 - 4:42 p.m.  |  Save Story

Both longtime fans of Greek food and first-timers can enjoy authentic Greek food at Pocatello's Assumption Greek Orthodox Church, friends and community on Nov. 7.

Merck drug extends survival in endometrial cancer trial, wins US priority review

Reuters  |  Updated Oct. 26 - 4:37 p.m.  |  Save Story

The US health regulator has accepted Merck's experimental targeted drug for a priority review ​based on data from a late-stage trial where it extended survival in women with an advanced form of endometrial cancer.